Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Inhibition of C1q, Initiator of the Classical Complement Cascade, by ANX005 for the Treatment of Guillain-Barré Syndrome: Results from a Phase 1b Study (763)

Zhahirul Islam, Nowshin Papri, Israt Jahan, Khan Abul Kalam Azad, Henk-André Kroon, Eric Humphriss, Sethu Sankaranarayanan, Ted Yednock, Sanjay Keswani, Quazi Deen Mohammad
First published April 14, 2020,
Zhahirul Islam
1icddr,b
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nowshin Papri
1icddr,b
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Israt Jahan
1icddr,b
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khan Abul Kalam Azad
2Dhaka Medical College and Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henk-André Kroon
3Annexon Biosciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Humphriss
3Annexon Biosciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sethu Sankaranarayanan
3Annexon Biosciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ted Yednock
3Annexon Biosciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Keswani
3Annexon Biosciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quazi Deen Mohammad
4National Institute of Neuroscience and Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Inhibition of C1q, Initiator of the Classical Complement Cascade, by ANX005 for the Treatment of Guillain-Barré Syndrome: Results from a Phase 1b Study (763)
Zhahirul Islam, Nowshin Papri, Israt Jahan, Khan Abul Kalam Azad, Henk-André Kroon, Eric Humphriss, Sethu Sankaranarayanan, Ted Yednock, Sanjay Keswani, Quazi Deen Mohammad
Neurology Apr 2020, 94 (15 Supplement) 763;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess anti-C1q antibody ANX005 in patients with Guillain-Barré Syndrome (GBS).

Background: GBS is a serious, life-threatening autoimmune disorder causing acute neuronal injury and progressive paralysis, sometimes leading to permanent disability or death. Symptoms peak within 4 weeks and recovery ranges from months to years. Although not FDA-approved, IVIg and plasma exchange are the standard of care in the US. Onset is associated with autoantibody-induced activation of the classical complement cascade. Inhibition of C1q, the initiating molecule of the cascade, early in the course of GBS may minimize disease severity and accelerate recovery.

Design/Methods: A phase 1b double-blind, placebo-controlled, single ascending dose study assessed safety, pharmacokinetics, and pharmacodynamics of ANX005 (n=23) vs placebo (n=8) in patients with GBS in Bangladesh. Neurofilament light chain (NfL), a nerve damage biomarker, and functional efficacy measures were assessed.

Results: In 23 patients aged 18–58 years, ANX005 infusions up to 75 mg/kg were well tolerated with no drug-related serious adverse events (AEs) or discontinuations. The most common AE was infusion-related reactions, manifesting as transient low-grade rashes. Doses ≥18 mg/kg fully inhibited C1q in serum and CSF; inhibition was sustained for up to 3 weeks with 75 mg/kg (n=6). ANX005 resulted in early decline in serum NfL vs placebo from week 2 to 4 post-dose (P=.012) and a dose-dependent improvement in Medical Research Council sum score at week 1. Early improvement correlated with GBS-Disability Score reduction (r2=0.48; P<.0001). At week 8, 28% of patients treated with ANX005 18–75 mg/kg improved by ≥3 points on GBS-Disability Score vs 0% with placebo. Trends for improvement were observed in length of ICU stay and duration of mechanical ventilation.

Conclusions: The classical complement inhibitor ANX005 was well tolerated and demonstrated robust target engagement, impact on biomarkers of neuronal damage, and preliminary evidence of efficacy. A phase 2 trial is planned.

Disclosure: Dr. Islam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Fogarty International Center, Department of Health and Human Services, National Institutes of Health, and Annexon Biosciences USA. Dr. Papri has nothing to disclose. Dr. Jahan has nothing to disclose. Dr. Azad has nothing to disclose. Dr. Kroon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon Biosciences. Dr. Humphriss has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon Biosciences. Dr. Sankaranarayanan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon Biosciences. Dr. Yednock has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon Biosciences. Dr. Keswani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon Biosciences. Dr. Keswani has received compensation for serving on the Board of Directors of Proneurotech. Dr. Deen Mohammad has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon Biosciences.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise